Baxter International Inc (BAX) concluded trading on Wednesday at a closing price of $34.41, with 6.2 million shares of worth about $213.42 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -12.29% during that period and on March 12, 2025 the price saw a loss of about -4.02%. Currently the company’s common shares owned by public are about 510.93M shares, out of which, 507.53M shares are available for trading.
Stock saw a price change of -2.13% in past 5 days and over the past one month there was a price change of 11.68%. Year-to-date (YTD), BAX shares are showing a performance of 18.00% which decreased to -21.38% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $28.33 but also hit the highest price of $43.99 during that period. The average intraday trading volume for Baxter International Inc shares is 4.96 million. The stock is currently trading 1.13% above its 20-day simple moving average (SMA20), while that difference is up 7.00% for SMA50 and it goes to 0.21% higher than SMA200.
Baxter International Inc (NYSE: BAX) currently have 510.93M outstanding shares and institutions hold larger chunk of about 96.30% of that.
The stock has a current market capitalization of $17.61B and its 3Y-monthly beta is at 0.62. It has posted earnings per share of -$1.27 in the same period. It has Quick Ratio of 1.05 while making debt-to-equity ratio of 1.93. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BAX, volatility over the week remained 3.50% while standing at 2.82% over the month.
Stock’s fiscal year EPS is expected to rise by 31.77% while it is estimated to increase by 9.81% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Goldman on February 26, 2025 offering a Buy rating for the stock and assigned a target price of $42 to it. On February 20, 2025, Barclays Resumed their recommendations, while on July 15, 2024, Morgan Stanley Downgrade their ratings for the stock with a price target of $30. Stock get a Neutral rating from Goldman on May 30, 2024.
